Innate Immune Responses in Chronic Obstructive Pulmonary Disease (COPD) Patients

Innate Immune Responses in Chronic Obstructive Pulmonary Disease Patients

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00826163

Enrollment

Registered

2009-01-21

Start date

2009-01-31

Completion date

2009-12-31

Last updated

2013-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Brief summary

We hypothesize that ongoing and more severe airway inflammation in COPD may result from the impairment in activation of innate immune response

Interventions

DRUGBudesonide

Inhaled budesonide 400 mcg twice a day for 2 weeks

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* clinical diagnosis of COPD or asthma * a ratio of prebronchodilator FEV1 to forced vital capacity (FVC) equal to or less than 0.70 * postbronchodilator FEV1 \> or = 50% predicted

Exclusion criteria

* Exacerbation * systemic corticosteroids * DM, HIV and autoimmune disease * immunosuppressive therapy

Design outcomes

Primary

Measure	Time frame
Sputum IL-8, IL-17	2 WEEKS

Secondary

Measure	Time frame
The expression of NF-kappa B in sputum macrophages	2 WEEKS

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026